In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...

Researchers at the University of Texas at Dallas, led by bioengineering associate professor Dr. Girgis Obaid, are partnering ...

Dr. Mostafa Madbouly, the Prime Minister, met on Monday, June 23, 2025, at the government headquarters in the New ...

Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without ...

PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer ...

Across dose levels 1 and 2, THE001 + RHT demonstrated a favorable safety profile. There were no dose-limiting toxicities or high-grade treatment-related adverse events that led to treatment ...

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths ...

PSRI, the best cancer specialist hospital in India, handles one of the highest oncology workloads in South Delhi.

A Moray mum has described how a suspected case of gallstones turned out to be a rare form of liver cancer following a ...